Caregivers Weigh In On CMS Insulin Pump Coverage: C-peptide Test Must Go
This article was originally published in The Gray Sheet
Executive Summary
CMS should eliminate its requirement that all patients seeking coverage for insulin pumps demonstrate abnormally low C-peptide levels, according to the American Association of Clinical Endocrinologists
You may also be interested in...
Medicare To Accept C-Peptide Test Alternative For Insulin Pump Coverage
CMS' modification to its insulin pump national coverage policy, while broadening access to the technology, falls short of Medtronic's full request
Medicare To Accept C-Peptide Test Alternative For Insulin Pump Coverage
CMS' modification to its insulin pump national coverage policy, while broadening access to the technology, falls short of Medtronic's full request
Insulin pump coverage criteria
Review of Medtronic MiniMed's April 1 request that CMS remove the C-peptide testing requirement from insulin pump national coverage criteria will be complete by Oct. 1. The American Association of Clinical Endocrinologists and other opinion leaders plan to send letters supporting the change. CMS maintains that C-peptide level assesses "residual beta-cell function by measuring insulin secretory ability and ensuring appropriateness of the infusion pump"...